ArticleBMJ open2025

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.

Alexios Matikas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.